Predictive value of inflammatory indices: a prospective study in critical oncological patients
DOI:
https://doi.org/10.53660/CONJ-1810-2L10Palavras-chave:
inflammation, critical care, neoplasms, prognosisResumo
O objetivo deste estudo foi avaliar a associação de índices inflamatórios e sobrevida em pacientes críticos com câncer. Trata-se de um estudo de coorte prospectivo, observacional, no qual os pacientes foram acompanhados por 28 dias após admissão na unidade de terapia intensiva (UTI) de um hospital de referência especializado em oncologia. A razão neutrófilo/linfócito (NLR), razão monócito/linfócito (MLR), razão plaqueta/linfócito (PLR) e Escore Prognóstico de Glasgow modificado (mGPS) foram calculados dentro de 24 horas após a admissão na UTI. A Correlação de Spearman, curva de sobrevida de Kaplan-Meier e regressão de Cox foram utilizadas para associar as variáveis selecionadas à sobrevida. Cem pacientes foram selecionados, dos quais 78% tinham câncer ativo e 27 foram à óbito. Pacientes com mGPS 1 e 2 tiveram uma probabilidade menor de sobrevida em 28 dias e foram 4,1 vezes mais propensos a morrer do que os pacientes com mGPS 0. O mGPS foi superior como preditor de sobrevida do que NLR, PLR e MLR em pacientes críticos diagnosticados com tumores sólidos. Mais estudos são necessários para estabelecer o ponto de corte preciso da mGPS em relação à mortalidade e avaliar sua aplicabilidade na prática clínica.
Palavras-chave: inflamação; cuidado crítico; neoplasias; prognóstico.
Downloads
Referências
ABE, T.; NAKATA, K.; KIBE, S.; et al. Prognostic value of preoperative nutritional and immunological factors in patients with pancreatic ductal adenocarcinoma. Ann Surg Oncol, v. 25, p. 3996–4003, 2018.
AZOULAY, E.; AFESSA, B. The intensive care support of patients with malignancy: do everything that can be done. Intensive Care Med, v. 32, n. 1, p. 3-5, 2006.
BRASIL. Ministério da Saúde. Portaria nº 3.432 de 12 de agosto de 1998. Estabelece critérios de classificação para as Unidades de Tratamento Intensivo – UTI. 1998. Disponível em: <http://bvsms.saude.gov.br/bvs/saudelegis/gm/1998/prt3432_12_08_1998.html>. Acesso em 09 de junho de 2020 às 13:40h.
BRAY, F.; FERLAY, J.; SOERJOMATARAM, I.; et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians. Hoboken, v. 68, n. 6, p. 394-424, 2018.
BROWN, J.; BYERS, T.; THOMPSON, K.; et al. Nutrition during and after cancer treatment: a guide for informed choices by cancer survivors. CA Cancer J Clin, v. 51, p. 153–187, 2001.
CHEN, P.; FANG, M.; WAN, Q.; et al. High-sensitivity modified Glasgow prognostic score (HS-mGPS) Is superior to the mGPS in esophageal cancer patients treated with chemoradiotherapy. Oncotarget, v. 8, n. 59, p. 99861-99870, 2017.
CROZIER, J.E.M.; LEITH, E.F.; MCKEE, R.F.; et al. Relationship between emergency presentation, systemic inflammatory response, and cancer-specific survival in patients undergoing potentially curative surgery for colon cancer. Am J Surg, v. 197, n. 4, p. 544–549, 2009.
DJORDJEVIC, D.; RONDOVIC, G.; SURBATOVIC, M.; et al. Neutrophil-to-Lymphocyte Ratio, Monocyte-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, and Mean Platelet Volume to-Platelet Count Ratio as Biomarkers in Critically Ill and Injured Patients: Which Ratio to Choose to Predict Outcome and Nature of Bacteremia? Mediators Inflamm, v. 15, 2018.
DOLAN, R.D.; DALY, L.; SIM, W.M.J.; et al. Comparison of the prognostic value of ECOG-PS, mGPS and BMI/WL: Implications for a clinically important framework in the assessment and treatment of advanced cancer. Clin Nutr, v. 39, n. 9, p. 2889-2895, 2020.
GUTHRIE, G.J.; CHARLES, K.A.; ROXBURGH, C.S.; et al. The systemic inflammationbased neutrophil-lymphocyte ratio: experience in patients with cancer. Crit Rev Oncol Hematol, v. 88, n. 1, p. 218–230, 2013.
GUO, W.; RAN, L.; ZHU, J.; et al. Identifying critically ill patients at risk of death from coronavirus disease. World J Emerg Med, v. 12, n.1, p. 18–23, 2021.
HU, Q.; GOU, Y.; SUN, C.; et al. The prognostic value of C-reactive protein in renal cell carcinoma: a systematic review and meta-analysis. Urol Oncol, v. 32, p. 32–50, 2014.
HWANG, S.Y.; SHIN, T.G.; JO, I.J.; et al. Neutrophil-to-lymphocyte ratio as a prognostic marker in critically-ill septic patient. Am. J. Emerg Med, v. 35, p. 234–239, 2017.
HAM, S.Y.; JIN YOON, H.; NAM, S.B.; et al. Prognostic value of neutrophil/ lymphocyte ratio and mean platelet volume/platelet ratio for 1 year mortality in critically ill patients. Nature, v. 10, p. 10:21513, 2020.
HIRAHARA, T.; ARIGAMI, T.; YANAGITA, S.; et al. Combined neutrophil-lymphocyte ratio and platelet-lymphocyte ratio predicts chemotherapy response and prognosis in patients with advanced gastric cancer. BMC Cancer, v. 19, n. 1, p. 672, 2019.
INCA. Instituto Nacional de Câncer José Alencar Gomes da Silva. Atlas on-line de mortalidade. Rio de Janeiro: INCA, 2019.
KANG, J.; CHANG, Y.; AHN, J.; et al. Neutrophil-to-lymphocyte ratio and risk of lung cancer mortality in a low-risk population: A cohort study. Int J Cancer, v. 145, n. 12, p. 3267-3275, 2019.
KEEGAN, M.T.; GAJIC, O.; AFESSA, B. Comparison of APACHE III, APACHE IV, SAPS 3, and MPM0III and influence of resuscitation status on model performance. Chest, v. 142, p. 851–858, 2012.
KNAUS, W.A.; ZIMMERMAN, J.E.; WAGNER, D.P.; et al. APACHE-acute physiology and chronic health evaluation: a physiologically based classification system. Critical Care Medicine, v. 9, n. 8, p. 591–597, 1981.
KNAUS, W.A.; DRAPER, E.A.; WAGNER, D.P.; et al. APACHE II: a severity of disease classification system. Critical Care Medicine, v. 13, n. 10, p. 818–829, 1985.
LE GALL, J.R. Modelling the severity of illness of ICU patients. JAMA, v. 272, n. 13, p. 1049-1055, 1994.
LIAO, D.W.; HU, X.; WANG, Y.; et al. C-reactive protein is a predictor of prognosis of prostate cancer: a systematic review and meta-analysis. Ann Clin Lab Sci, v. 50, p. 161–71, 2020.
LIBERSKI, P.S.; SZEWCZYK, M.; KRZYCH, L.J. Haemogram-Derived Indices for Screening and Prognostication in Critically Ill Septic Shock Patients: A Case-Control Study. Diagnostics, v. 10, p. 638, 2020.
MCMILLAN, D.C. The systemic inflammation-based Glasgow Prognostic Score: A decade of experience in patients with cancer. Cancer Treatment Reviews, v. 39, n. 5, p. 534-40, 2013.
NIEWINSKI, G.; KANSKI, A. Mortality scoring in ITU. Anaesthesiol Intensive Ther. v. 44, p. 47–50, 2012.
NOGUEIRA, L.S.; SANTOS, M.R.; MATALOUN, S.E.; et al. Nursing Activities Score: comparison among the Index APACHE II and the mortality in patients admitted in intensive care unit. Revista Brasileira De Terapia Intensiva, v. 19, n. 3, p. 327–330, 2007.
SHELTON, B.K. Admission criteria and prognostication in patients with cancer admitted to the intensive care unit. Critical Care Clinics, v. 26, n. 1, p. 1–20, 2010.
PETRELLA, F.; RADICE, D.; CASIRAGHI, M.; et al. Glasgow Prognostic Score Class 2 Predicts Prolonged Intensive Care Unit Stay in Patients Undergoing Pneumonectomy. Ann Thorac Surg, v. 102, n. 6, p. 1898-1904, 2016.
PITRE, T.; JONES, A.; SU, J.; et al. Infammatory biomarkers as independent prognosticators of 28 day mortality for COVID 19 patients admitted to general medicine or ICU wards: a retrospective cohort study. Intern Emerg Med 2021.
PROCTOR, M.J.; MORRISON; D.S.; TALWAR, D.; et al. A comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow Inflammation Outcome Study. Eur J Cancer, v. 47, p. 2633–41, 2011.
RODRIGUES, C.M.; PIRES, E.M.C.; FELICIANO, J.P.O.; et al. Admission factors associated with intensive care unit readmission in critically ill oncohematological patients: a retrospective cohort study. Rev Bras Ter Intensiva, v. 29, n. 1, p. 33–39, 2016.
SALCICCIOLI, J.D.; MARSHALL, D.C.; PIMENTEL, M.A.F.; et al. The association between the neutrophil-tolymphocyte ratio and mortality in critical illness: an observational cohort study. Critical Care, v. 19, n. 1, p. 13, 2015.
SIQUEIRA, A.; TIBURCIO, J. Estatística na área da saúde: conceitos, metodologia, aplicações e prática computacional. Belo Horizonte, 2011.
SHAFIQUE, K.; PROCTOR, M.J.; MCMILLAN, D.C..; et al. Systemic inflammation and survival of patients with prostate cancer: evidence from the Glasgow Inflammation Outcome Study. Prostate Cancer Prostatic Dis, v. 15, p. 195–201, 2012.
SHIMIZU, T.; TANIGUCHI, T.; ASAKUMA, M.; et al. Lymphocyte-to-Monocyte Ratio and Prognostic Nutritional Index Predict Poor Prognosis in Patients on Chemotherapy for Unresectable Pancreatic Cancer. Anticancer Res, v. 39, n. 4, p. 2169-2176, 2019.
SINGER, M.; DEUTSCHMAN, C.S.; SEYMOR, C.W.; et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA, v. 315, n.8, p. 801–810, 2016.
TANEJA, R.; PARODO, J.; JIA, S.H.; et al. Delayed neutrophil apoptosis in sepsis is associated with maintenance of mitochondrial transmembrane potential and reduced caspase-9 activity. Crit Care Med, v. 32, n.7, p. 1460-1469, 2004.
WALSH, S.R.; COOK, E.J.; GOULDER, F.; et al. Neutrophil-lymphocyte ratio as a prognostic factor in colorectal cancer. J Surg Oncol, v. 91, p. 181–184, 2005.
WIGMORE, T.J.; FARQUHAR-SMITH, P.; LAWSON A. Intensive care for the cancer patient – Unique clinical and ethical challenges and outcome prediction in the critically ill cancer patient. Best Practice & Research Clinical Anaesthesiology v. 27, n.4, p. 527–543, 2013.
ZAHOREC, R. Ratio of neutrophil to lymphocyte counts — rapid and simple parameter of systemic inflammation and stress in critically ill. Bratisl Lek Listy, v. 102, n. 1, p. 5-14, 2001.
VIDAL, A.C.; HOWARD, L.E.; DE HOEDT, A.; et al. Neutrophil, lymphocyte and platelet counts, and risk of prostate cancer outcomes in white and black men: results from the SEARCH database. Cancer Causes Control, v. 29, n. 6, p. 581-588, 2018.
Downloads
Publicado
Como Citar
Edição
Seção
Licença
Copyright (c) 2022 Conjecturas
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
